rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Talphera, Inc.

TLPH · Nasdaq

Health CareBiotechnologyIn trend

TLPH stood above a rising 150-day average in 27 of the last 52 weekly readings, including each of the last 12 weeks. It is 3.9% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
12 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$608K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
46 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$345KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Vincent J. AngottiCHIEF EXECUTIVE OFFICERbought213,310at $0.58613 Mar 2026filed 25 Mar 2026
Badri N. DasuChief Engineering Officerbought35,000at $0.812312 Feb 2026filed 20 Feb 2026
Raffi AsadorianChief Financial Officerbought45,000at $0.812312 Feb 2026filed 20 Feb 2026
Vincent J. AngottiCHIEF EXECUTIVE OFFICERbought105,364at $0.812312 Feb 2026filed 20 Feb 2026
Shakil AslamChief Medical Officerbought35,000at $0.812312 Feb 2026filed 20 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders46+3 on the quarter
New · exited12 · 9
Reported value$24.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rosalind Advisors, Inc.added · filed 14 Aug 20265,169,501$5.3M+1,815,585+54.1%
AIGH Capital Management LLCreduced · filed 7 Aug 20264,601,502$4.7M-60,000−1.3%
Rock Springs Capital Management LPunchanged · filed 14 Aug 20263,589,186$3.7M00.0%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 20263,492,519$3.6M00.0%
Bleichroeder LPunchanged · filed 13 Aug 20261,307,787$1.3M00.0%
CANTOR FITZGERALD, L. P.unchanged · filed 14 Aug 2026887,481$914K00.0%
Dauntless Investment Group, LLCadded · filed 13 Aug 2026746,051$768K+310,817+71.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026701,877$723K+260,266+58.9%
Caption Management, LLCreduced · filed 14 Aug 2026514,969$530K-46,851−8.3%
Almitas Capital LLCunchanged · filed 17 Aug 2026467,152$481K00.0%
31 Mar 2023 – 30 Jun 2026
243545Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Abhinav Jain Company insiderDirector · last 22 Jun 20260 · 0
Adrian Adams Company insiderDirector · last 22 Jun 20264 · 0
Jill Marie Broadfoot Company insiderDirector · last 22 Jun 20260 · 0
Joseph Todisco Company insiderDirector · last 22 Jun 20260 · 0
Marina Bozilenko Company insiderDirector · last 22 Jun 20260 · 0
Mark A. Wan Company insiderDirector · last 22 Jun 20260 · 2
Stephen J. Hoffman Company insiderDirector · last 22 Jun 20262 · 0
Shakil Aslam Company insiderChief Medical Officer · last 20 May 20263 · 0
Badri N. Dasu Company insiderChief Engineering Officer · last 2 Apr 20262 · 1
Raffi Asadorian Company insiderChief Financial Officer · last 2 Apr 20268 · 1
Vincent J. Angotti Company insiderCHIEF EXECUTIVE OFFICER · last 2 Apr 202620 · 0
Nantahala Capital Management, LLC Company insider10% owner, Other · last 13 Mar 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-52.0%
Share count trendFY 2025 · to 18 Mar 20261.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.9M

Analyst forecasts

No analyst forecasts yet.